Retinal DREADD Delivery for Cell-Specific Neural Pathway Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic treatments for nervous system diseases and disorders lack cell-type specificity, leading to inefficacy despite psychological interventions, and direct neurosurgical methods for DREADD injection into the brain pose challenges.
Innovation Solution
A method involving the administration of a viral vector containing a promoter and DREADD to retinal cells, followed by an agonist administration, to target and stimulate specific neurological pathways, particularly the brain nucleus locus coeruleus, using a more physiologically natural approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If direct brain injection of DREADDs is performed, then cell-type specificity is achieved, but neurosurgical complications and invasiveness increase
Solution Approach 1:
The patent uses the eye and retinal cells as an intermediary access point to deliver DREADDs to the brain. By injecting viral vectors into the eye, DREADDs are expressed in retinal cells which then naturally project to brain nuclei (such as the locus coeruleus), allowing indirect but specific targeting of brain regions without direct brain surgery. This intermediary approach maintains cell-type specificity while avoiding the harmful effects of direct neurosurgery.
2Ease of operation
If systemic administration of DREADDs is performed, then ease of administration is improved, but cell-type specificity is reduced
Solution Approach 1:
The patent employs cell-type-specific promoters (such as the PACAP promoter) that are selectively active in specific neuronal populations. When the viral vector is administered systemically or into the eye, these promoters ensure that DREADDs are expressed only in the desired cell types (e.g., PACAP-positive neurons in the retina that project to the locus coeruleus), thereby maintaining cell-type specificity despite easy administration routes.
3Reliability
If direct stimulation of locus coeruleus neurons is performed, then therapeutic effect is achieved, but physiological naturalness is reduced
Solution Approach 1:
The patent uses DREADDs to preliminarily equip specific neurons with the ability to be selectively activated or inhibited by designer drugs. This preliminary genetic modification allows for physiological and natural manipulation of neural circuits because the DREADD-expressing neurons can be activated by endogenous-like signaling mechanisms, preserving the natural physiology of the targeted pathways while achieving reliable therapeutic effects.
Data Source
AI summary
Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.